Nordic Capital forms a leading European dental clinic platform

Nordic Capital

Funds advised by Nordic Capital (“Nordic Capital”) today announced the formation of a leading European dental clinic group, comprising the acquisition of three fast-growing and quality focused dental clinic chains in the Netherlands, Switzerland and Germany, as well as an innovative dental technology and laboratory company with a strong base in the German market (the “Group”).

As part of the transactions, Nordic Capital has signed agreements to acquire Top Mondzorg BV, the owner of Dental Clinics Nederland and TopOrtho (“Dental Clinics”) with a combined 88 clinics in the Netherlands and Adent Cliniques Dentaires Groupe SA (“Adent”) with 22 clinics in Switzerland. Nordic Capital acquired Adent and Dental Clinics from Oaktree Capital Management. In addition, Nordic Capital has agreed to acquire DPH Dental Partner Holding GmbH, Germany’s largest dental laboratory operator and SFE Beteiligungsgesellschaft mbH, the owner of Zahnstation, the Cologne-based dental clinic chain with 6 locations.

Nordic Capital intends to continue the investment into the Group’s leading quality standards, best-in-class operating model and strong local brands, which are recognised for the best clinical environments, leading edge technology and highly trained staff by patients and dentists alike. With its scale and expanding presence in the most attractive European dental care markets, the Group will be at the forefront of innovation, remaining focused on providing the best dental care for its patients.

“Through these acquisitions Nordic Capital will establish a leader in the European dental services markets with best in class operational capabilities and a strong track record of organic and acquisitive growth. The European dental care markets remain very fragmented and there is significant potential to continue to actively drive consolidation. We aim to draw on Nordic Capital’s extensive experience from ownership of high quality and rapidly expanding healthcare clinic chains, including the leading European veterinary care provider AniCura, to capitalise on this growth opportunity. We look forward to working together with management to continue to grow the Group in its existing markets in the Netherlands, Switzerland, Germany, and beyond” says Jonas Agnblad, Partner, Advisor to the Nordic Capital Funds.

Nordic Capital is a leading healthcare investor with a 25-year track record of building high quality, sustainable healthcare businesses in Europe and the US.

The transactions are subject to customary regulatory approvals.


Media contacts:

Katarina Janerud, Communications Manager
Advisor to the Nordic Capital Funds
Tel: +46 8 440 50 50

About Dental Clinics

Dental Clinics is an innovative, leading dental care provider in the Netherlands with 88 dental and orthodontic clinics operating under the Dental Clinics and TopOrtho brands. The modern clinics offer a full range of general and specialist dental treatments and serve more than 500,000 patients annually. The Company was founded in 2007 and has subsequently expanded through organic growth and a successful clinic acquisition strategy. Dental Clinics’ patient-oriented operating model is underpinned by strong focus on team work, relentless quality management and an efficient organisation. The Company is focused on offering high quality dental care in a modern and safe environment.

About Adent

Adent is a quality focused dental chain with 22 large clinics in Switzerland, and the only Swiss dental care provider operating across the French and German speaking regions of the country. The Company was founded in 1997 when the first clinic was opened in Ecublens, and has subsequently expanded through clinic acquisitions and the opening of new sites. Adent’s clinics offer a full range of general and specialist dental treatments, and operate extended opening hours in accessible locations to ensure best service and quality of care for its patients.

About Dental Partner Holding

Dental Partner Holding is a leading European provider of high technology dental laboratory services, operating a country-wide network of 35 laboratories in Germany under the Flemming Dental brand together with 3 locations in Norway under the Artinorway brand. Founded in 1998, the Company is headquartered in Hamburg with a technology centre in Leipzig for the modern, digitally enabled manufacturing of dental prostheses. The Company’s operations are based on the highest quality standards, comprehensive local services to dentists and efficient centralised manufacturing using the latest digital technologies.

About Zahnstation

Zahnstation is a fast-growing dental chain in Germany, currently operating a network of 6 dental clinics in the Cologne area. Zahnstation’s clinics offer a range of general and specialist dental treatments, with a focus on high quality care and patient convenience through extended opening hours and accessible locations.

About Nordic Capital

Nordic Capital private equity funds have invested in mid-market companies primarily in the Nordic region since 1989. Through committed ownership and by targeting strategic development and operational improvements, Nordic Capital enables value creation in its investments. The Nordic Capital Funds invest in companies in northern Europe and in selected investment opportunities internationally. The most recent fund is Nordic Capital Fund VIII with EUR 3.5 billion in committed capital, principally provided by international institutional investors such as pension funds. The Nordic Capital Funds are based in Jersey, Channel Islands, and are advised by the NC Advisory companies in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital please see

Categories: News


Gilde Healthcare company RAD-x continues Buy & Build with acquisition of Swiss Medical Imaging Centers

GIlde Healthcare

Utrecht, The Netherlands – RAD-x, a France-based operator in diagnostic imaging and a portfolio company of Gilde Healthcare, announced that it has acquired Swiss Medical Imaging Investment SA (SMII), which operates the imaging centres Centre d’Imagerie Médicale de la Chaux-de-Fonds, Centre d’Imagerie Médicale du Chablais and Centre d’Imagerie Médicale du Chablais Valaisan.

SMII is a leading diagnostic imaging provider in the Swiss cantons of Neuchâtel, Vaud and Valais and was founded and developed by the radiology entrepreneur Dr. Pierre Chevalley, who as part of this transaction becomes a shareholder in RAD-x.

With the acquisition of SMII, RAD-x expands its national reach and capabilities and strengthens its position as the partner of choice for diagnostic imaging centres and radiologists by combining medical excellence with state of the art management capabilities. With this transaction RAD-x is now able to offer the full range of imaging services from general to very specialized imaging as well as interventional radiology. Next to its expansion in Switzerland, RAD-x is progressing on its development in Germany and France.


About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and Dach-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Since 2001 Gilde Healthcare has raised €800 million ($1 billion) for its specialized funds. For more information, visit the company’s website at

Gilde Healthcare


Categories: News


Stone Point Capital to acquire Genex Services from Funds advised by Apax Partners

Apax Digital

Wayne, PA, – Feb. 9, 2018 – Genex Services (“Genex”), a leading provider of cost containment services to the workers’ compensation, disability and auto industries, announced today that funds managed by private equity firm Stone Point Capital LLC (”Stone Point”) have entered into a definitive agreement to acquire a majority interest in Genex from funds advised by Apax Partners, a global private equity firm. The transaction is expected to close in the first quarter of 2018.

Founded in 1978, Genex helped introduce the medical management concept and has become one of the largest and most experienced medical cost containment and disability management providers today. Genex offers a broad continuum of services including utilization management, case management, bill review, independent medical examinations, Medicare Set-Asides, and Social Security Disability Insurancerepresentation.

“This transaction renews a successful partnership between Genex and Stone Point. Stone Point had previously acquired the company in 2007 before selling to the Apax Funds in 2014. Both Apax Partners and Stone Point have been strong business partners of Genex and supported the expansion of its service capabilities both organically and through acquisitions,” said Peter Madeja, Genex’s President and Chief Executive Officer.

“We are excited to partner with Stone Point,” said Madeja. “Genex is a well-established leader in workers’ compensation, auto, and disability management solutions. Our partnership with Apax Partners allowed us to significantly expand our portfolio of solution offerings across the continuum of managed care. We believe that Stone Point’s commitment to continue to grow and enhance Genex’s capabilities will further enrich the value proposition we offer to customers through the depth and breadth of resources we bring to the market.”

Andrew Cavanna, Partner at Apax Partners, added: “We would like to thank Peter and the rest of the management team for being excellent partners over the past four years and for successfully growing Genex’s business and capabilities. We wish the team every success for the future.”

“We are thrilled to be partnering with Peter and the Genex team again to further their continued expansion within the markets they serve,” added Chuck Davis, CEO of Stone Point.  “We have a strong relationship with Peter and his talented management team, which has been developed over more than ten years, and we now look forward to the opportunity to support Genex as the company continues to build upon its long history of success.”

SunTrust Robinson Humphrey served as the exclusive strategic and financial advisor to Genex. Financial terms were not disclosed.

About Genex Services, LLC
Genex Services ( is the trusted provider of managed care services enabling clients to transform their bottom lines while enhancing the lives of injured and disabled workers. Genex is a managed care leader with more than 2,900 employees and 41 service locations throughout North America. The company serves the top underwriters of workers’ compensation, automobile, disability insurance, third-party administrators and a significant number of Fortune 500 employers. In addition, Genex is the only company that delivers high-quality clinical services enhanced by intelligent systems and 360-degree data analysis. The company consistently drives superior results related to medical, wage loss, and productivity costs associated with claims in the workers’ compensation, disability, automobile, and health care systems.

About Stone Point Capital
Stone Point Capital LLC ( is a financial services-focused private equity firm based in Greenwich, CT.  The firm has raised and managed seven private equity funds – the Trident Funds – with aggregate committed capital of approximately $19 billion.  Stone Point targets investments in the global financial services industry, including investments in companies that provide outsourced services to financial institutions, banks and depository institutions, asset management firms, insurance and reinsurance companies, insurance distribution and other insurance-related businesses, specialty lending and other credit opportunities, mortgage services companies and employee benefits and healthcare companies.

About Apax Partners
Apax Partners ( is a leading global private equity advisory firm. Over its more than 35-year history, Apax Partners has raised and advised funds with aggregate commitments of $51 billion*. Apax Partners’ Main Buyout Funds invest in companies across four global sectors of Tech & Telco, Services, Healthcare and Consumer. These funds provide long-term equity financing to build and strengthen world-class companies.

* Funds raised since 1981, commitments converted from fund currency to USD at FX rates as at 31 December 2017.

Media Contacts

Genex Services
Tom Kerr, Genex Services | +1 610-964-5213 |

Apax Partners
Global Media: Andrew Kenny, Apax | +44 20 7 872 6371 |
USA Media: Todd Fogarty, Kekst | +1 212-521 4854 |
UK Media: Matthew Goodman / James Madsen, Greenbrook | +44 20 7952 2000 |

Stone Point Capital
Jim Henderson | +1 203-862-3162 |
Mary Manin | +1 203-862-3126 |

Categories: News


Gilde Healthcare invests in business intelligence for healthcare by acquiring Performation

GIlde Healthcare

Utrecht, The Netherlands – Gilde Healthcare today announces the acquisition of Performation, market leader in business intelligence for healthcare in the Netherlands. The investment of Gilde Healthcare will facilitate the expansion of the company’s service offering to improve operational, tactical and strategic control of healthcare clients.

Healthcare business intelligence is growing fast
Business intelligence is an essential tool in modern hospital management. Reports on quality, costs and operations provide vital input to managers taking decisions. The demand for business intelligence in the healthcare sector is forecast to grow by 10-15% annually. “Better insights on the effectiveness of the care delivered not only enables increasing quality of care, but also has the potential to decrease its costs,” comments Hugo de Bruin, partner with Gilde Healthcare.

Broadening service offering
Performation has grown rapidly over the last years. “The investment by Gilde Healthcare enables us to introduce new services to manage and control the quality of healthcare companies. We will continue to develop new products in house, such as our successful Notiz product for DRG registration assurance. In addition, we will consider acquiring companies with strong existing service offerings to add to our platform,” says Steven Lugard, CEO of Performation. “The recent acquisition of revenue forecasting provider Datinzo is an example of this. It strengthens our position as a full range business intelligence supplier for the healthcare sector.”

Improving healthcare delivery
The investment in Performation fits well with the profile of Gilde Healthcare as a specialist investor. De Bruin: “We are constantly looking for companies that positively contribute to the quality of healthcare delivery. Performation’s partnership with IKNL is a good example of this value add. Performation supports the Dutch cancer research foundation in reporting treatment outcomes. With this information, cancer care in the Netherlands is constantly improved. Demand for healthcare information is growing, not only with healthcare managers, but also among patients and doctors. Performation is a leading expert in extracting this data and transforming it into the desired information.”

About Performation
Performation Healthcare Intelligence is a provider of healthcare specific business intelligence solutions to monitor costs, processes and quality. The company supports clients in taking well-informed decisions that contribute to the delivery of high quality and effective care. With over a hundred enthusiastic consultants and business intelligence experts, Performation is a leading player in the Dutch market.

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Since 2001 Gilde Healthcare has raised €800 million ($1 billion) for its specialized funds. For more information, visit the company’s website at

Categories: News


Gimv invests in FIRE1, a medtech company developing a connected novel heart monitoring solution


Gimv today announced a EUR 7 million investment in Ireland-based The Foundry Innovation and Research 1, Ltd. (FIRE1), a medtech company that is developing a connected monitoring solution to improve outcomes for people suffering from an increased risk of heart failure.This investment is part of a Series C financing of in total EUR 40 million from a strong syndicate of specialised investors, led by new investor Gilde Healthcare, with the participation of new investors Gimv and Seventure as well as all existing investors.

FIRE1 ( is the 15th medical device company and the 1st European spin-out from The Foundry, a successful Menlo Park, California-based medical device company incubator. FIRE1’s first product is a novel remote monitoring solution to improve outcomes for patients suffering from an increased risk of heart failure. Early detection enables a timely intervention and adjustment of pharmacotherapy, the Us avoiding hospitalisation, improving quality of life and lowering health care costs.

FIRE1 is led by an experienced medical devices team working closely with researchers, clinicians, patients and payers to help reduce the burden of heart failure.

Patrick Van Beneden, Partner in Gimv’s Health & Care platform, on this transaction: “We are very pleased to be involved in FIRE1, a company with an experienced team That is developing a new monitoring device for heart failure. This is a market with growing unmet needs, as cardiac disease is currently the world’s leading cause of death. This financing represents one of the bigger medtech transactions in Europe over the last months and is supported by an outstanding investor syndicate.”

The current financing, in which existing investors New Enterprise Associates, Lightstone Investors and Medtronic are also participating, will be used to complete a first-in-human study as well as for the submission of an IDE.


Gimv is a European investment company with almost 38 years’ experience in private equity and venture capital. Listed on Euronext Brussels, Gimv currently manages around 1.6 billion EUR (including co-investment partnerships) of investments in about 50 portfolio companies.

As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are: Connected Consumer, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv’s home markets of the Benelux, France and Germany and can count on an extended international network of experts.

More information on Gimv can be found on

For further information please contact:

Patrick Van Beneden, Partner in Gimv’s Health & Care platform

T +32 3290 2136 –


Frank De Leenheer, Investor Relations & Corporate Communications Manager

Gimv T +32 3 290 22 18 –


Categories: News


EQT Mid Market to sell I-MED Radiology Network to Permira


  • EQT Mid Market to sell diagnostic imaging service company I-MED Radiology Network to the Permira funds
  • EQT Mid Market invested in I-MED in April 2014 together with Singaporean Sovereign Wealth fund GIC and Caisse de dépôt et placement du Québec, one of Canada’s leading institutional fund managers
  • During EQT Mid Market’s ownership, I-MED has had substantial organic growth, increased scale through multiple add-on acquisition, invested significantly in new equipment and technology and enhanced operating efficiency

The EQT Mid Market fund (“EQT Mid Market”) has, together with co-investors, entered into an agreement to sell I-MED Radiology Network (”I-MED” or “the Company”) to a company backed by the Permira funds.

I-MED is the leading diagnostic imaging service provider in Australia with 204 clinics and performs almost five million procedures per year. During EQT Mid Market’s ownership, the Company has grown the number of fully owned clinics with more than 30% and the number of radiologist by more than 25%. I-MED has during the last three years further strengthened its market position in Australia and for 2017 generated revenues of almost AUD 700 million. I-MED has a strong and dedicated staff with over 3,500 employees, including more than 300 radiologists who serve over 30,000 referrers in the growing healthcare market in Australia.

  • During the ownership of EQT Mid Market, I-MED has successfully enhanced its business on multiple fronts:
  • Achieved strong organic growth through establishing new clinics and entering new hospital contracts
  • Successfully completed a number of value accretive add-on acquisitions
  • Made significant investments into equipment, new technology and people
  • Implemented strategies for further enhancing the customer experience

Steven Rubic, CEO of I-MED, said: “We are proud to have been part of EQT, one of the world’s most respected global investment firms, with a strong experience within the healthcare sector. EQT have supported I-MED’s growth focused strategy and their ownership approach has provided us with a solid foundation for I-MED’s further growth.”

Fredrik Åtting, Partner at EQT Partners, Investment Advisor to EQT Mid Market, added: “We are very impressed by I-MED’s management, doctors and staff for the professional and consistent service they provide to the Australian healthcare system. Through a combination of organic and inorganic growth, I-MED has evolved into the undisputed market leader in Australia. It has been a privilege to support I-MED’s management team under the leadership of Paul McClintock and Steven Rubic.”

The transaction is expected to close in Q1 2018.

Morgan Stanley acted as financial advisor and Herbert Smith Freehills as legal advisor to EQT Mid Market.

Fredrik Åtting, Partner at EQT Partners, Investment Advisor to EQT Mid Market, +49 892 554 9950

EQT Press Contact, +46 8 506 55 334

About EQT
EQT is a leading alternative investments firm with approximately EUR 38 billion in raised capital across 25 funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info:

About I-MED
I-MED is one of the world’s leading diagnostic imaging providers. It was formed in 2000 and offers comprehensive and high-quality services including X-ray, PET, CT, MRI, Nuclear Medicine, Ultrasound, Mammography and Interventional Procedures. Across Australia, I-MED operates 204 clinics covering all major metropolitan areas and significant parts of rural Australia. Each year almost 5 million patient procedures are performed by I-MED’s more than 300 radiologists, 50 nuclear medicine physicians, and 3,500 staff.

More info:

Categories: News


Mérieux Développement and Gimv announce the signature of an exclusivity agreement with a view to acquiring Stiplastics Healthcaring


Mérieux Développement and Gimv, together with the management team, announce that they have signed an exclusivity agreement with Stage Capital, Stiplastics Healthcaring’s majority shareholder, with a view to acquiring the company.

Stiplastics Healthcaring, which was founded in 1985 and has been owned by Stage Capital (formerly NBGI) since 2013, designs, develops and manufactures standard and smart plastic solutions for the pharmaceutical industries and the health sector. Based in Saint-Marcellin (Isère – France), the company currently employs over 90 people on a 10,000 m2 industrial site opened last October. The Group expects to achieve turnover of EUR 21 million in the current 2017/2018 financial year, 98% of which will be generated by the health sector. Exports account for 55% of Stiplastics’ turnover, thanks to its development of devices for the dispensing of solid-form medications (especially in the USA).

Stiplastics Healthcaring has over 30 years’ experience in medical plastics. It works with customers throughout the entire process, from formulating the exact needs until the product is launched. It is a recognised specialist in the area of treatment observance, and its range of “intelligent” pill dispensers encourage treatment observance, and make administering and taking medicines easier and safer. It has also built solid expertise in solutions for respiratory diseases. Stiplastics Healthcaring works in partnership with pharmaceutical industry leaders and has recently developed an inhalation device.

The company has a strong development potential in the connected health sector, with new products in the pipeline and a modern workshop for the production of electronic products in a controlled environment. In order to meet the new needs of patients and healthcare actors faced with changing pathologies and uses, and more specifically the increasing prominence of connected care, the Group has set up its IoC [Internet Of Care]® unit, which is dedicated to designing, developing and producing e-health medical devices. In addition, several partnership agreements were finalised in 2017 in what is an extremely promising sector, which will benefit patients and practitioners alike.

Mérieux Développement and Gimv[1] have joined forces to acquire Stiplastics Healthcaring. They will contribute their complementary expertise in the health sector and support the growth of this French company. Stiplastics Healthcaring will remain under the operational management of Jérôme Empereur and Laetitia Le Gall, who have successfully developed this high-performing industrial platform, whilst creating real sales momentum in recent years.

“The Mérieux Développement – Gimv consortium is an ideal tandem that will allow Stiplastics Healthcaring to grow further and accelerate its development. They bring to the table health sector specialists as well as substantial financial resources, which is perfectly suited to support the Group’s growth challenges” explained Jérôme Empereur, Stiplastics Healthcaring’s Chairman-CEO.

Our decision to invest in Stiplastics Healthcaring is based on our assessment of the strength of the management team and our shared ambition on the company’s future. In particular, we have jointly identified the increased need for innovative solutions to improve observance and administration of medicines. We are delighted to be the new reference shareholder of this French company and to be given this opportunity to support its innovative strategy and international development plans.” says Jean-François Billet, Senior Partner at Mérieux Développement.

“Stiplastics Healthcaring has all the necessary assets to become a European market leader, including cutting-edge production facilities, excellent regulatory expertise and a deep understanding of its clients’ needs. We are very proud that Jérôme Empereur and the entire management team have chosen the Mérieux Développement-Gimv consortium to support them in their ambitious growth plans,” adds Benoit Chastaing, Partner Health & Care at Gimv.

The transaction is expected to close by the end of January 2018. No further financial details about this transaction will be disclosed.


Categories: News


Eurazeo Patrimoine announces the acquisition of C2S GROUP

No Comments


Eurazeo Patrimoine, the Eurazeo division specializing in investments in tangible assets, is pleased to announce the acquisition of C2S Group from Bridgepoint. The investment company will invest c. €100 million to become the group’s majority shareholder, alongside management and medical practitioners.

The transaction is subject to the approval of the French Competition authority and should be completed in the first quarter of 2018. C2S Group is the eighth largest private clinic operator in France and a regional leader in Auvergne, Rhône-Alpes and Burgundy Franche-Comté. It operates 11 clinics, primarily specializing in short and medium-length stays in general medicine, surgery and follow-up care. It also wns the buildings for seven of its clinics. The group has 500 medical practitioners, who are partners in the group’s governance and nearly 1,800 employees. In 2016, it treated over 235,000 patients (75% as outpatients) and reported revenue of €158 million. The group’s growth is founded on long-term societal trends. The French hospital care market was €195 billion 2015 (second largest in Europe) and is growing steadily.

C2S also enjoys an ideal regional footprint in one of the most densely populated and attractive areas in France. C2S Group has strengthened the management of its operations and real estate assets, while implementing an active external growth strategy,acquiring notably Hôpital Privéd’Ambérieu in 2015 and the Avenir Santé Group in 2016.

Since 2015, it has invested heavily in modernizing the group and improving its operating performance, benefiting from a relationship of trust with regional health authorities. Eurazeo Patrimoine’s experience in accompanying companies, combined with its real estate management expertise and its historical knowledge of the region, will drive the acceleration of C2S Group’s development, particularly through external growth.

For Renaud Haberkorn, Managing Partner and Head of Eurazeo Patrimoine: “We’re thrilled to offer our real estate and operational support and expertise to C2S Group. Its development and transformation in recent years has been quite remarkable. With its strong local footprint and Eurazeo Patrimoine’s support, we’re sure the group will continue its growth momentum and seize the many development opportunities available to it. This investment fits perfectly with Eurazeo Patrimoine’s strategy at the crossroads of the real estate and private equity businesses.”

For Jean Rigondet, Chairman of C2SGroup: “We’re delighted to welcome Eurazeo onboard and to work together to continue the group’s development strategy. With Bridgepoint ’s support, we successfully completed several projects and undertook essential work across all our clinics. We’re now eager to start a new chapter in C2S Group’s history alongside Eurazeo Patrimoine.

Further improvements in performance will be founded on exemplary medical governance and our teams, of which we are immensely proud, confirming our position in the Greater Center-East region.”

About Eurazeo

With a diversified portfolio of approximately ~€8 billion in assets under management, Eurazeo is a leading global investment company with offices in Paris and Luxembourg, New York, Shanghai and Sao Paolo. Its purpose and mission is to identify, accelerate and enhance the transformation potential of the companies in which it invests. The firm covers most private equity segments through its five business divisions – Eurazeo Capital, Eurazeo Croissance, Eurazeo PME, Eurazeo Patrimoine and Eurazeo Brands. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term. As a global long-term shareholder, the firm offers deep sector expertise, a gateway to global markets, and a stable foothold for transformational growth to the companies it supports.

Eurazeo is listed on Euronext Paris.

ISIN: FR0000121121 – Bloomberg: RF FP – Reuters: EURA.PA



Categories: News


ONELA, Colisée’s new home care services Brand Name


Paris – January 15th 2018 – Colisée reaffirms its commitment to senior citizens and their loved ones’ care with the launch of its Brand Name ONELA, Bien à la Maison and Nouvel Horizon Services’ new common Brand Name.

With close to 70 agencies, ONELA, home services specialist, is abundantly present throughout the country, without brand franchising, in order to insure standardized values and good practices shared by its 2900-employee staff. ONELA is renowned for the quality of the services it provides to elderly and handicapped people as well as people in recovery and their caregivers.

Thanks to their proximity, responsiveness and 24-hour activity the ONELA teams are able to meet the needs expressed in all circumstances by more than 12.000 beneficiaries daily.

ONELA emphasizes its demanding recruitment process and its training policy devised to ensure an efficient and homogeneous service. With this objective, ONELA fully profits from the Colisée Group’s renowned expertise, both in France and internationally, in the elderly people’s sector.

To outline its difference, ONELA relies on a strong identity highlighted by its motto “Etre bien chez soi” (“Feeling good at home”) and new additional services such as tele-advice or teleconsultation: a 24-hour, 7 days a week medical service which makes it possible for someone to get in touch strictly confidentially with a doctor in order to talk, get some advice or reassurance and if necessary be directed towards an appropriate service.

With its brand-new redesigned website ( which promotes both the staff and the agencies and boasts a recruiting section and an easily noticeable identity, ONELA will endeavour to find and offer regular new services, truly suited to the current expectations of senior citizens who would like to live independently and at home as long as possible.

Categories: News


Partners Group sells stake in Victorian Comprehensive Cancer Centre in Melbourne, Australia

Partners Group

Partners Group, the global private markets investment manager, has, on behalf of its clients, sold its 21% stake in the Victorian Comprehensive Cancer Centre (“VCCC” or “the Centre”), a cancer research, treatment and education centre in Melbourne, Australia, to AMP Capital’s Community Infrastructure Fund.

Partners Group was part of the winning Plenary Health consortium selected by the Victorian Government in late 2011 to deliver the VCCC in a public-private-partnership (PPP) project. As Australia’s first dedicated, state-of-the-art cancer research and treatment facility, the Centre was envisaged to save lives through the integration of research, education and patient care. The PPP project scope included the design, construction and commissioning of the VCCC facilities as well as their ongoing maintenance under a 25-year concession agreement. The completed Centre has 13 levels, 160 inpatient beds, 110 day beds and eight operating theatres, and can host up to 1,200 researchers. Plenary Health completed the VCCC on time and on budget at a total cost of AUD 1 billion and operations began seamlessly in June 2016.

Benjamin Haan, Partner, Head of Private Infrastructure Asia, Partners Group, states: “We are immensely proud of having supported the Victorian Government in realizing its innovative vision for the future of cancer care by delivering this critical social infrastructure project on time and within budget, alongside our consortium partners. With the facility now fully operational, and having received strong interest from potential buyers, Partners Group decided to divest its stake in this groundbreaking Centre ahead of the original investment plan to an experienced investor with a long-term investment horizon and a socially responsible investment remit.”

Partners Group continues to be a strong supporter of Australian PPP projects on behalf of its clients. In September 2014, it announced it was investing into the PPP project to build and operate the new Sydney Metro Northwest rail service for the New South Wales Government. In November 2016, the firm announced it would be investing in Melbourne’s High Capacity Metro Trains PPP, an AUD 2 billion project to deliver 65 trains to the State of Victoria.

Categories: News